Forge Biologics’ cover photo
Forge Biologics

Forge Biologics

Biotechnology Research

Columbus, Ohio 27,703 followers

A member of Ajinomoto Bio-Pharma Services

About us

Forge, a member of Ajinomoto Bio-Pharma Services, is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.

Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Columbus, Ohio
Type
Privately Held
Founded
2020
Specialties
AAV, Gene Therapy, Biotech, and cGMP

Locations

Employees at Forge Biologics

Updates

  • View organization page for Forge Biologics

    27,703 followers

    🎮 Bill of materials, Band of Brothers, and a passion for planning—meet Cait Ogilbee, our latest Genes of Interest spotlight! Over the past four years at Forge, Cait has gone from managing our loading docks to helping lead the charge on cGMP material planning as a Supply Chain Planner. From helping introduce our inventory system to optimizing forecasts and supporting our ERP system, she has been instrumental in keeping our operations running smoothly. Find out which classic war drama tops her watchlist, which PS5 game she's playing right now, and why you’ll probably catch her near the yogurt parfaits in the social hub. Read the full spotlight here ➡️ https://bit.ly/3IYketk

    • No alternative text description for this image
  • Better manufacturing starts with better design. At Forge, we work alongside gene therapy developers to strengthen every step of the manufacturing process, including the often overlooked molecular foundation. With firsthand experience navigating scale-up, we know how critical early design decisions are to long-term success. Low yields or inconsistent capsid expression? Your rep/cap plasmid might be the missing link. As part of our FUEL™ platform, our modified rep/cap plasmids help developers: • Boost yields without altering the capsid protein sequence • Seamlessly integrate into our proprietary backbone plasmid • Scale with confidence while reducing development risk Built for manufacturability, backed by experience, and designed to help your therapy reach the clinic faster. Fuel more ➡️ https://bit.ly/4fo4I69

  • 6 new hires, 5 departments, 1 shared mission. This week, we welcomed six incredible team members to Forge, each bringing expertise and vision to a team dedicated to enabling access to life-changing therapies by helping bring them from concept into reality. We’re more than 400 strong and hiring! Come fuel the future of gene therapy manufacturing ➡️ https://bit.ly/45fw0H6

    • No alternative text description for this image
  • 🚴 Crossing the finish line with purpose! This past weekend, 9 Forge team members rode over 300 miles in Pelotonia, a powerful movement rooted in our Columbus community and driven by one goal: to end cancer. We’re proud to support not only the ride, but the meaningful fundraising that fuels world-class cancer research with global impact. Our team’s dedication reflects the spirit of Forge and the strength of a community united by purpose. #Pelotonia #OneGoal #ForgeWithUs

    • No alternative text description for this image
  • Scaling AAV manufacturing without sacrificing quality? It’s possible. For gene therapy developers navigating the complexities of scale-up and regulatory expectations, FUEL™ is more than a platform—it’s a strategic advantage. Built by AAV experts, FUEL™ combines advanced technologies, cGMP-proven processes, and tailored optimization packages to reduce development risk while accelerating timelines. Whether you're solving upstream bottlenecks or preparing for pivotal milestones, our platform helps you achieve the efficiency, consistency, and compliance your program demands. Explore our full capabilities here ➡️ https://bit.ly/41idL2s

  • 🎉 Happy National Intern Day! This week, our brilliant class of nine interns is wrapping up their projects and gearing up for final presentations. From curiosity to creativity, they've brought energy, fresh ideas, and unwavering dedication to Forge's mission throughout their time here this summer. To celebrate their contributions, they hit up Top Golf with their managers. Thank you, interns, for everything you’ve brought to Forge this summer!

    • No alternative text description for this image
  • 🚨 ICYMI: 23 Questions with Lauren Hall!   We recently caught up with Lauren Hall, MS, PMP, a project manager on our PMO team, to learn how she keeps complex client programs moving forward and what she does outside of work to stay focused and inspired.   From SmartSheets tips to her favorite reads, Lauren gives us a behind-the-scenes look at her routines, priorities, and what makes her tick.   Catch her 23 rapid-fire answers here ➡️ https://lnkd.in/gj-qM4rj

  • Same product, different batch size. How does this affect my BLA submission? When it comes to filing your BLA,  comparability data  isn’t just a checkbox, it’s the gatekeeper to approval. For AAV gene therapies, consistency in potency, purity, and full/empty capsid ratio is non-negotiable. At Forge, we help you bridge the clinical-to-commercial gap with harmonized assays, in-house analytics, and deep regulatory know-how—so your product holds up, batch after batch. Read more about the BLA filing process here ➡️ https://hubs.li/Q03z6BND0

  • View organization page for Forge Biologics

    27,703 followers

    From Tokyo with innovation 🇯🇵💡 We’re heading home energized by the incredible gene therapy community at #JSGCT. It was an honor to share the week with our colleagues at Ajinomoto and connect with the inspiring developers from across Japan and APAC. Rachael Hardison, Ph.D., shared how our FUEL™ platform is helping gene therapy teams streamline manufacturing and bring their breakthroughs to patients faster. Here’s to continued collaboration!

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +1

Similar pages

Browse jobs

Funding

Forge Biologics 5 total rounds

Last Round

Series C

US$ 90.0M

See more info on crunchbase